Sign In
Buy RHHBY
$49.15
-0.610 (-1.23%)
At Close: Jun 22, 2026
EXEL Down on Colorectal Cancer Study Data on Zanzalintinib
03:26pm, Tuesday, 23'rd Jun 2026
Exelixis falls after STELLAR-303 misses statistical significance in overall survival for a key colorectal cancer subgroup, raising approval uncertainty.
U.S.-Iran deal will stick despite being a ‘bad, bad deal', says David Roche
12:15am, Friday, 19'th Jun 2026
Quantum Strategy's David Roche expects the US-Iran deal to hold, arguing both Washington and Tehran have strong incentives to keep Iranian oil flowing and avoid political disruption ahead of US midter
FDA Accepts Roche's Filing for Lunsumio VELO-Polivy in LBCL
01:50pm, Thursday, 18'th Jun 2026
FDA accepts RHHBY filing for Lunsumio VELO plus Polivy in relapsed or refractory LBCL as a potential chemotherapy-free treatment option.
FDA approves first generic version of Roche's flu drug
06:35pm, Wednesday, 17'th Jun 2026
The U.S. Food and Drug Administration approved the first generic version of Roche's Xofluza, a single-dose flu medicine for certain patients aged five years and older, the regulator said on Wedn
JAZZ's Zepzelca Fails to Meet Primary Goal in Lung Cancer Study
01:21pm, Monday, 15'th Jun 2026
Jazz Pharmaceuticals' Zepzelca fails a phase III lung cancer study, but strong first-line uptake and 2026 guidance remain unchanged.
Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer
03:15pm, Friday, 12'th Jun 2026
The new VENTANA PTEN (SP218) RxDx Assay fulfils an unmet medical need by helping clinicians identify patients with PTEN protein loss who may benefit from combination treatment with TRUQAP In prostate
Roche's Tecentriq Plus Chemo Gets FDA Priority Tag for Colon Cancer
10:47am, Thursday, 11'th Jun 2026
RHHBY wins FDA priority review for Tecentriq plus FOLFOX6 in stage III dMMR/MSI-H colon cancer, with a decision due in October 2026.
Nurix Therapeutics Deal With Roche Is Worth Betting On
09:48am, Thursday, 11'th Jun 2026
Recently, Nurix secured a partnership with Roche, which I believe has substantially derisked the stock as a whole. Similarly, this deal helps validate NRIX's bexobrutideg and its potential as a broade
Roche Vs. Pfizer: Obesity Week Presentations Deep Dive - What Investors Must Know
01:44pm, Wednesday, 10'th Jun 2026
Roche Holding AG and Pfizer Inc. are aggressively advancing obesity and T2D pipelines to capture share in the surging GLP-1 market. RHHBY's enicepatide shows strong Phase 2 weight loss data (22.7% at
Nurix Therapeutics: 'Strong Buy' Due To Roche Deal And Bexobrutideg Expansions
09:59am, Tuesday, 09'th Jun 2026
Nurix Therapeutics, Inc. remains a Strong Buy as bexobrutideg advances in pivotal r/r CLL trials and secures a transformative $2.3B global partnership with Roche. Bexobrutideg demonstrates superior ef
Roche sticks to German investment after Eli Lilly cuts
03:39am, Tuesday, 09'th Jun 2026
The Swiss pharmaceutical and diagnostics giant Roche said it is sticking to its planned investments in Germany, unlike some of its competitors that have scaled back spending in the country.
Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
06:48pm, Monday, 08'th Jun 2026
Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
Roche's $2.3 Billion Nurix Deal Sends Shares Moving
02:35pm, Monday, 08'th Jun 2026
Roche Holding AG (RHHBY) has agreed to pay Nurix Therapeutics (NRIX) as much as $2.3 billion for rights to bexobrutideg, an experimental pill targeting certain
Roche, Nurix Team Up to Advance BTK Degrader Bexobrutideg
12:46pm, Monday, 08'th Jun 2026
Roche collaborates with Nurix on bexobrutideg, a BTK degrader for blood cancers, while expanding potential use into immunology and neurology.
BAYRY or RHHBY: Which Is the Better Value Stock Right Now?
12:41pm, Monday, 08'th Jun 2026
Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both Bayer Aktiengesellschaft (BAYRY) and Roche Holding AG (RHHBY). But which of these two stocks presents invest
